News

December 7, 2018December 7, 2018

S100A12 May Be Potential Prognostic Biomarker in Juvenile Idiopathic Arthritis, Study Suggests

News

The protein S100A12 can potentially be used as a biomarker for disease activity and a therapy’s effectiveness in juvenile idiopathic arthritis, a study found. The study, “A Granulocyte-Specific Protein ... Read more

November 30, 2018November 30, 2018

FDA Approves Genentech’s Actemra Autoinjector For Some Juvenile Arthritis, Other Indications

News

The U.S. Food and Drug Administration (FDA) has approved ACTPen, a single-dose, pre-filled autoinjector of Actemra (tocilizumab) to be administered in children 2 and older who have active polyarticular juvenile idiopathic arthritis ... Read more

November 16, 2018November 16, 2018

In JIA, Abnormality of Blood Cells is Seen in Bone Marrow, Researchers Find

News

Disrupted blood cell production and markedly high rates of inflammation are seen in patients with juvenile idiopathic arthritis (JIA), Chinese researchers report. The study, “Characteristics of bone marrow cells ... Read more

November 9, 2018November 9, 2018

FDA Approves Sandoz’s Hyrimoz, Biosimilar to Humira, for Juvenile Arthritis, Other Diseases

News

The U.S. Food and Drug Administration has granted approval to Sandoz’s Hyrimoz (adalimumab-adaz), a biosimilar to Abbvie’s Humira. FDA approval includes indications for seven diseases, including juvenile idiopathic arthritis for ... Read more

November 2, 2018November 2, 2018

Charitable Book is Told Through the Eyes of Critically Ill Children

News

After a chance meeting in a New York City restaurant with a young boy who shared what life was like with brain cancer, Samantha Hasen was moved to raise ... Read more

October 22, 2018October 22, 2018

Amgen Launches Humira Biosimilar, Amgevita, in Markets Across Europe

News

Amgen recently launched Amgevita, a biosimilar to Abbvie’s Humira (adalimumab), in Europe after approval by the European Commission. The therapy will be available in the 28 countries of the European Union, ... Read more

October 19, 2018October 19, 2018

Imraldi, BioSimilar to Humira, Now Available in Europe to Treat JIA, Other Conditions

News

Imraldi, an adalimumab biosimilar of reference product Humira from AbbVie, will now be available to patients in the European Union, Samsung Bioepis the therapy’s maker, recently announced. In August 2017, the European Commission approved ... Read more

October 8, 2018October 8, 2018

Exercise and Psychological Training May Help to Ease Chronic Pain in Juvenile Arthritis

News

Non-pharmacological treatments, such as psychological and exercise-based interventions, may be a viable way of easing pain in children and teenagers with pediatric rheumatic disease, also known as juvenile arthritis, a ... Read more

October 1, 2018October 1, 2018

Humira Biosimilar Hulio Granted Marketing Authorization in Europe for JIA, Others

News

Mylan and Fujifilm Kyowa Kirin Biologics were granted marketing authorization for biosimilar Hulio (adalimumab) by the European Commission for all the indications of its reference product, AbbVie‘s Humira (adalimumab), including ... Read more

September 21, 2018September 21, 2018

FDA Approves Subcutaneous Form of Actemra for Active Systemic Juvenile Idiopathic Arthritis

News

The U.S. Food and Drug Administration (FDA) has approved Genentech’s formulation of Actemra (tocilizumab) by subcutaneous injection for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in children ages 2 and ... Read more

Pin It on Pinterest